Followers | 128 |
Posts | 2150 |
Boards Moderated | 1 |
Alias Born | 12/27/2007 |
Friday, July 14, 2017 12:47:29 PM
In early June 2017, the FDA canceled a tentative joint Anesthetic and Analgesic Drug Products and Drug Safety and Risk Management Advisory Committee meeting in connection with its review of the Company’s New Drug Application (NDA) for DSUVIA for the treatment of moderate-to-severe acute pain. Andrews believes the reason in part has to do with the uncontroversial product profile; thus the analyst believes Dsuvia will be approved on its October 12, 2017, PDUFA date.
"While the FDA under Dr. Gottlieb is focused on addressing the U.S.’s opioid crisis, we believe this will largely focus on the appropriate use and duration of chronic (not acute) opioid therapy. The CHMP’s decision on the Dsuvia MAA in Europe is expected in H1 2018, and the EMA has already approved Zalviso (a 15mcg tablet of sufentanil). We probability weight our U.S. and Europe Dsuvia estimates at 75% and 80%, respectively," Andrews said.
The analyst concluded, "ACRX is under-valued due to potent oral opioid Dsuvia's promise in medicallysupervised acute pain markets (~92M patients) and we see high likelihood of U.S./EU approvals in Q4'17/H1'18. Risk/reward is favorable into H1'18 with floor of ~$1.25 (no approvals) vs. $12/share (upside scenario)."
https://finance.yahoo.com/news/jefferies-sees-strong-upside-acelrx-145225845.html
Recent TLPH News
- Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/05/2024 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:22:55 PM
- Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit • PR Newswire (US) • 08/19/2024 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2024 09:22:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:12:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:10:32 PM
- Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 08:01:00 PM
- Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024 • PR Newswire (US) • 08/05/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:19:26 PM
- Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 05/20/2024 09:25:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/20/2024 09:22:15 PM
- Talphera to Participate at A.G.P. Virtual Healthcare Conference • PR Newswire (US) • 05/16/2024 09:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:00:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:15:28 PM
- Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/14/2024 08:05:00 PM
- Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024 • PR Newswire (US) • 05/02/2024 08:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:11:29 PM
- Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:55:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:54:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:53:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 12:35:13 PM
- Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members • PR Newswire (US) • 03/01/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 02:06:44 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM